申请人:KALLUS Christopher
公开号:US20080262028A1
公开(公告)日:2008-10-23
The present invention is directed to a compound of formula I:
or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.
本发明涉及一种式I化合物:
或式I化合物的任何立体异构体形式,或这些形式的任何比例的混合物,或式I化合物的生理可接受盐,该化合物抑制酶TAFIa(活化的凝血酶可激活的纤维蛋白溶解抑制剂),以及涉及它们的制备方法及其用于治疗说明书中所述疾病的使用,其中取代基如说明书中所述。